Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

This is the authors' abstract. We don't add key points for this paper.

This analysis confirms previously reported data that nemolizumab relieves itch and sleep disturbance by Day 2 in patients with moderate-to-severe AD and PN, indicating that targeting the IL-31 pathway presents an important way to achieve rapid itch response.